Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival Celebration Sale - 2019
Google
Web www.equitybulls.com
Stock Report

| More

Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia

Posted On: 2019-10-03 10:07:08

Biocon Ltd and Mylan N.V. today announced the launch of Semglee® (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen), the first insulin glargine biosimilar in Australia available on the Pharmaceutical Benefits Scheme (PBS).

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar levels of those with diabetes. It is indicated for the treatment of type 1 diabetes mellitus in adults, adolescents and children aged six years and above and type 2 diabetes mellitus in adults. Diabetes is recognised as the world's fastest growing chronic condition and is the biggest challenge confronting Australia's health system. Almost two million Australians have diabetes, with 280 Australian developing diabetes every day - one person every five minutes. The total annual cost impact of diabetes in Australia is estimated at $14.6 billion.

More affordable treatment options for healthcare providers and their patients, such as biosimilars, generate savings that help manage the growing costs of Australia's health care system, particularly the PBS.

The Government recognises the importance of driving biosimilar uptake to create a competitive and sustainable biosimilars market. In 2015, the Government committed to the Biosimilar Awareness Initiative and in 2018 increased its commitment by supporting the Generic and Biosimilar Medicines Association through a $5 million grant to undertake activities that further promote the appropriate prescribing, dispensing and use of biosimilar medicines.

Dr Christiane Hamacher, CEO, Biocon Biologics said, "We are extremely excited to enable affordable access to Semglee, a high quality biosimilar Insulin Glargine, co-developed and manufactured by Biocon Biologics, to people with diabetes in Australia. We are committed to use our science, scale and expertise to shift the access paradigm for patients in need of insulins across the globe. As a leading global insulins player, Biocon has been addressing the needs of patients with diabetes for over 15 years and we are confident that availability of Semglee through the Pharmaceutical Benefits Scheme will expand patient access to this therapy in Australia and will reduce the cost burden for PBS. Today, patients in Europe, India and key emerging markets are already benefiting from our biosimilar Insulin Glargine."

Mylan Australia Country Manager, Sylvain Vigneault commented, "The launch of Semglee further demonstrates Mylan's ongoing commitment to increase access to biosimilars for patients. Biosimilars mark a new era in treatment. They enable more patients to be treated, deliver significant savings to the PBS and help provide sustainability to the healthcare system overall.

"We are delighted that Semglee enables Mylan to strengthen and support its global diabetes and metabolism portfolio of approximately 400 products."

Biosimilars have been used safely and effectively in Europe, USA, Australia and many other countries. Since 2006, in the EU alone, over 700 million patient days of clinical experience to more than 20 biosimilar medicines have been recorded.

TGA approval of Semglee, co-developed by Biocon and Mylan, was based on robust data that demonstrated that Semglee is highly similar to the reference insulin glargine, with no clinically meaningful differences in efficacy, safety, purity and potency.

Mylan and Biocon's insulin glargine biosimilar is currently approved in more than 40 countries around the world.

Shares of BIOCON LTD. was last trading in BSE at Rs.222.7 as compared to the previous close of Rs. 223. The total number of shares traded during the day was 193560 in over 2464 trades.

The stock hit an intraday high of Rs. 228.95 and intraday low of 221.4. The net turnover during the day was Rs. 43554591.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

MCX Q2 FY2019-20 consolidated PAT surges to Rs. 71.75 crore

ACC Ltd Q3 consolidated PAT at Rs. 302.53 crore

Uttam Galva Steels Ltd posts loss of Rs. 335.45 crores in Q2

SBI Life Insurance Company Ltd announces performance for half year ended Sep 30, 2019

CRISIL reaffirms ratings of Raymond's bank loan facilities

Hindustan Zinc Ltd Board to consider Q2 results & First Interim Dividend on Oct 21, 2019

ARSS Infrastructure Projects Ltd's JV receives work order of Rs. 60.57 crore

ACC Ltd announces Q3 CY2019 results

Robust Volumes on MCX Drive Strong Performance in Q2 FY 2020

ONGC Videsh makes two new discoveries in Colombia and Brazil

Suditi Industries Ltd updates on ratings by CARE

Thangamayil Jewellery Ltd to open two new branches on Oct 16, 2019

Gujarat Hotels Ltd Q2 net profit rises to Rs. 1.07 crore

Wipro Limited Q2 Net Income at Rs. 25.5 billion

Karnataka Bank records first half net profit of Rs. 281.33 crore

Scanpoint Geomatics bags contract for Rs. 3.99 crore

ARSS Infrastructure Projects Ltd's JV bags order of Rs. 50.46 crore

Karnataka Bank reports net profit of Rs. 105.91 crore

Alicon Castalloy Ltd reports consolidated Q2 PAT of Rs. 9.35 crore

WIPRO Ltd Q2 consolidated PAT climbs to Rs. 2552.7 crore

Dhanvarsha Finvest Ltd assigned credit rating for proposed long term facility

ICRA Credit Rating for Rs 500 Crore bank facilities of Ramco Industries Limited

Dhanvarsha Finvest Ltd posts net profit of Rs. 1.03 crore in Q2

International Travel House Ltd Q2 loss at Rs. (2.12) crore

Paisalo Digital Ltd posts consolidated Q2 PAT of Rs. 20.04 crores

Apollo Tricoat Tubes Ltd Q2 net profit jumps to Rs. 9.42 crores

Equinor extends IT Operations and Transformation Agreement with HCL

Network18 Media & Investments Ltd announces Q2 FY2019-20 results

TV18 Broadcast Limited announces Q2 FY20 results

G G Engineering Ltd acquires additional stake in Shashi Beriwal and Company Pvt Ltd

Z F Steering Gear India Ltd posts loss of Rs. 0.80 crore in Q2

Berger Paints India Ltd to acquire STP Limited for Rs. 167.5 crore

Kaveri Seeds sets up its biggest, technologically advanced Biotechnology lab in Telangana, strengthens its focus on R & D

Maruti Suzuki invests Rs. 154 crore towards CSR initiatives in FY 2018-19

IOL Chemicals & Pharmaceuticals Ltd prepays Rs. 22.11 crore to bank

Jindal Drilling and Industries Limited awarded contract for Offshore Drilling Rig

CARE reaffirms ratings of Havells India Ltd

Indiabulls Housing Finance Limited repays Rs. 1330 crores raised through masala bonds

YES BANK recovers INR 645 crore

Vikas WSP Ltd receives LoC for $30 mn

CRISIL upgrades ratings of Varun Beverages Ltd

HUL Announces Key Appointments to Management Committee

GTPL Hathway appoints Mr. Anil Bothra as its Chief Financial Officer

Brickwork reaffirms ratings of Transcorp International Ltd

TCS Named India's Overall Most Outstanding Company in Asiamoney's 2019 Poll

Tejas Networks launches World's Largest Disaggregated Packet-Optical Switch at India Mobile Congress 2019

Cummins India powering a cleaner and more prosperous India with their BS-VI Certified engines

Early Diwali for investors: IRCTC stock doubles on listing day

Hindustan Unilever Ltd board declares interim dividend of Rs. 11 for 2019-20

Thomas Cook India introduces a unique 'Double Protection Program' comprising Trip Protection + Guaranteed Departures aimed at protecting traveller interests







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019